AXGN vs. EDAP, OM, SMLR, ZYXI, ELMD, FONR, VANI, HYPR, GLUE, and DSGN
Should you be buying AxoGen stock or one of its competitors? The main competitors of AxoGen include Edap Tms (EDAP), Outset Medical (OM), Semler Scientific (SMLR), Zynex (ZYXI), Electromed (ELMD), FONAR (FONR), Vivani Medical (VANI), Hyperfine (HYPR), Monte Rosa Therapeutics (GLUE), and Design Therapeutics (DSGN). These companies are all part of the "medical" sector.
AxoGen (NASDAQ:AXGN) and Edap Tms (NASDAQ:EDAP) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, risk, analyst recommendations, community ranking, dividends, valuation, earnings and profitability.
In the previous week, Edap Tms had 4 more articles in the media than AxoGen. MarketBeat recorded 8 mentions for Edap Tms and 4 mentions for AxoGen. AxoGen's average media sentiment score of 1.23 beat Edap Tms' score of -0.01 indicating that AxoGen is being referred to more favorably in the media.
AxoGen presently has a consensus target price of $10.67, indicating a potential upside of 76.60%. Edap Tms has a consensus target price of $14.00, indicating a potential upside of 108.64%. Given Edap Tms' higher possible upside, analysts plainly believe Edap Tms is more favorable than AxoGen.
AxoGen has a net margin of -12.99% compared to Edap Tms' net margin of -30.12%. AxoGen's return on equity of -22.18% beat Edap Tms' return on equity.
AxoGen has a beta of 1.07, meaning that its share price is 7% more volatile than the S&P 500. Comparatively, Edap Tms has a beta of 0.65, meaning that its share price is 35% less volatile than the S&P 500.
80.3% of AxoGen shares are held by institutional investors. Comparatively, 62.7% of Edap Tms shares are held by institutional investors. 7.0% of AxoGen shares are held by insiders. Comparatively, 0.2% of Edap Tms shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
AxoGen has higher revenue and earnings than Edap Tms. Edap Tms is trading at a lower price-to-earnings ratio than AxoGen, indicating that it is currently the more affordable of the two stocks.
AxoGen received 100 more outperform votes than Edap Tms when rated by MarketBeat users. Likewise, 72.48% of users gave AxoGen an outperform vote while only 62.84% of users gave Edap Tms an outperform vote.
Summary
AxoGen beats Edap Tms on 14 of the 17 factors compared between the two stocks.
Get AxoGen News Delivered to You Automatically
Sign up to receive the latest news and ratings for AXGN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AXGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
